HEART: Cardio-visual Stimulation in Augmented Reality for Pain Reduction
Study Details
Study Description
Brief Summary
The objective of this study is to evaluate the feasibility and efficacy of an Augmented Reality (AR) biofeedback intervention to alleviate pain symptoms in individuals suffering from chronic pain of the hand and/or the forearm.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Chronic pain is a major public health problem with implications for high health care costs, lost productivity and an estimated financial burden of $500 billion. Individuals with chronic pain are also at an increased risk of developing an opioid use disorder.
Chronic pain has previously been associated with a distorted body representation, in particular of the affected body parts. Virtual Reality (VR) studies using embodiment-, respiration-, and heart-beat related feedback have demonstrated positive effects for induced pain in healthy participants (e.g., increased pain thresholds) and chronic pain in patient populations (e.g., decreased subjective pain, improved functionality, improved physiological markers of pain). Based on these studies, the AR intervention evaluated here aims to alleviate subjective pain symptoms and improve physiological pain markers in chronic pain patients using heartbeat-related feedback.
This within-subject study will compare subjective pain ratings before, during, and after an AR intervention that provides visual feedback of participants' on-going heartbeat in relation to their affected limb. Primary outcomes include subjective reports from participants (perceived efficacy, acceptability, and demand) and the intervention's clinical feasibility, including reports from therapists. Secondary outcomes include changes in heart rate and variability.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Experimental 1: HEART - Placebo - HEART - Placebo The patient receives visual feedback in an augmented reality environment in four session, over two weeks. Week 1: HEART, Placebo (after >24hour washout) Week 2: HEART, Placebo (after >24hour washout) |
Device: HEART
In an augmented reality environment, the patient receives visual feedback in synchrony with their cardiac-cycle (HEART)
Device: Placebo
In an augmented reality environment, the patient receives visual feedback out-of-synchrony with their cardiac cycle (Placebo)
|
| Experimental: Experimental 2: HEART - Placebo - Placebo - HEART The patient receives visual feedback in an augmented reality environment in four session, over two weeks. Week 1: HEART, Placebo (after >24hour washout) Week 2: Placebo, HEART (after >24hour washout) |
Device: HEART
In an augmented reality environment, the patient receives visual feedback in synchrony with their cardiac-cycle (HEART)
Device: Placebo
In an augmented reality environment, the patient receives visual feedback out-of-synchrony with their cardiac cycle (Placebo)
|
| Experimental: Experimental 3: Placebo - HEART - Placebo - HEART The patient receives visual feedback in an augmented reality environment in four session, over two weeks. Week 1: Placebo, HEART (after >24hour washout) Week 2: Placebo, HEART (after >24hour washout) |
Device: HEART
In an augmented reality environment, the patient receives visual feedback in synchrony with their cardiac-cycle (HEART)
Device: Placebo
In an augmented reality environment, the patient receives visual feedback out-of-synchrony with their cardiac cycle (Placebo)
|
| Experimental: Experimental 4: Placebo - HEART - HEART - Placebo The patient receives visual feedback in an augmented reality environment in four session, over two weeks. Week 1: HEART, Placebo (after >24hour washout) Week 2: Placebo, HEART (after >24hour washout) |
Device: HEART
In an augmented reality environment, the patient receives visual feedback in synchrony with their cardiac-cycle (HEART)
Device: Placebo
In an augmented reality environment, the patient receives visual feedback out-of-synchrony with their cardiac cycle (Placebo)
|
Outcome Measures
Primary Outcome Measures
- Change in perceived pain [change in pain rating will be evaluated when participants first wear the Head-Mounted Display (baseline), after 3 minutes of video-passthrough (Pre), after 3 minutes of cardio-visual stimulation (post), after 3 minutes of video-passthrough (final)]
The patient moves a cursor on a Visual Analog Scale to indicate their currently perceived level of pain. The gauge ranges from "no pain" (0) to "worst pain imaginable" (10).
- Change in Heart-Rate Variability (time domain) [a change in heart-rate variability will be evaluated between baseline (pre), intervention, and immediately following intervention (post)]
time-domain metrics of heart-rate variability [ms]
- Change in Heart-Rate Variability (frequency domain) [a change in heart-rate variability will be evaluated between baseline (pre), intervention, and immediately following intervention (post)]
frequency-domain metric of heart-rate variability (power)
Secondary Outcome Measures
- Questionnaire [The first day of the study]
Questionnaire on the sensations, usability, and satisfaction with the augmented reality stimulation using a Visual Analog Scale (0-10) where higher scores indicate agreement with the questionnaire item.
- Questionnaire [The second day of the study]
Questionnaire on the sensations, usability, and satisfaction with the augmented reality stimulation using a Visual Analog Scale (0-10) where higher scores indicate agreement with the questionnaire item.
- Questionnaire [The third day of the study]
Questionnaire on the sensations, usability, and satisfaction with the augmented reality stimulation using a Visual Analog Scale (0-10) where higher scores indicate agreement with the questionnaire item.
- Questionnaire [The fourth day of the study]
Questionnaire on the sensations, usability, and satisfaction with the augmented reality stimulation using a Visual Analog Scale (0-10) where higher scores indicate agreement with the questionnaire item.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Be over 18 years of age
-
Present permanent chronic pain (for more than 3 months), secondary to a peripheral pathology (traumatic, orthopedic or neurological), located in the hand or forearm.
Exclusion Criteria:
-
Pregnant women
-
People in emergency situations
-
Persons unable to give informed consent
-
Persons who are mentally or linguistically unable to understand the research test instructions
-
Individuals who are not available to complete the entire study protocol
-
Cognitive impairments that prevent the use of the equipment
-
Psychiatric disorders
-
Patients with seizure disorders
-
Patients with central hemineglect
-
Pain secondary to central nervous system pathology
-
Patients with arrhythmia
-
Patients with head tremors or head shaking.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Institut Régional de Médecine Physique et de Réadaptation | Nancy | France | 54000 |
Sponsors and Collaborators
- Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est
- Mindmaze SA
Investigators
- Principal Investigator: Jean Paysant, Pr, UGECAM Nord Est
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IRR-CLP-2019-4